About

Oak Hill Bio Holdings Ltd (formerly known as Oak Hill Bio Ltd) is developing OHB-607, a replacement therapy designed to prevent complications of prematurity in extremely preterm infants which is currently in a phase 2b study and is a shareholder of its subsidiary OHB Pediatrics Ltd (operating under the trading name Oak Hill Bio). OHB Pediatrics' lead program is rugonersen (OHB-724), an investigational oligonucleotide entering Phase 3 for the treatment of Angelman syndrome, a devastating neurodevelopmental disorder with no approved disease-modifying therapies. For more information about OHB Pediatrics Ltd, please visit www.oakhillbio.com